​

Foghorn Therapeutics (FHTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

FHTX Stock Forecast

Foghorn Therapeutics (FHTX) stock forecast, based on 12 Wall Street analysts, predicts a 12-month average price target of $4.00, with a high of $5.00 and a low of $2.00. This represents a 99.00% increase from the last price of $2.01.

High: $5 Avg: $4 Low: $2 Last Closed Price: $2.01

FHTX Stock Rating

Foghorn Therapeutics stock's rating consensus is Buy, based on 12 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (66.67%), 4 Hold (33.33%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 12 4 8 0 Strong Sell Sell Hold Buy Strong Buy

FHTX Price Target Upside V Benchmarks

TypeNameUpside
StockFoghorn Therapeutics99.00%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts558
Avg Price Target$4.00$4.00$6.88
Last Closing Price$2.01$2.01$2.01
Upside/Downside99.00%99.00%242.29%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2619---10
Sep, 2619---10
Aug, 2619---10
Jul, 2619---10
Jun, 2619---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 13, 2026Evercore ISI$3.00$1.9553.85%49.25%
Oct 02, 2026Andrew FeinH.C. Wainwright$5.00$2.9271.23%148.76%
Oct 02, 2026Guggenheim$5.00$2.9271.23%148.76%
Oct 02, 2026Robert DriscollWedbush$2.00$2.92-31.51%-0.50%
Oct 01, 2026Laura PrendergastStifel Nicolaus$5.00$2.6886.57%148.76%
Feb 17, 2026Jefferies$12.00$5.55116.22%497.01%
Dec 18, 2025BTIG$11.00$4.64137.07%447.26%
Dec 03, 2025Stifel Nicolaus$12.00$4.44170.27%497.01%
Dec 17, 2024Foghorn Therapeutics to $H.C. Wainwright$13.00$6.26107.67%546.77%
Sep 24, 2024Vikram PurohitMorgan Stanley$9.00$9.32-3.43%347.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 02, 2026H.C. WainwrightBuyBuyhold
Oct 02, 2026WedbushNeutraldowngrade
Oct 02, 2026GuggenheimBuyBuyhold
Oct 01, 2026Cowen & Co.Holddowngrade
Oct 01, 2026BTIGBuyNeutraldowngrade
Oct 01, 2026CitigroupMarket PerformPerformdowngrade
Oct 01, 2026CitigroupMarket OutperformMarket Performdowngrade
Sep 17, 2026CitigroupMarket OutperformMarket Outperformhold
Mar 12, 2026JefferiesBuyBuyhold
Dec 18, 2025BTIGBuyinitialise

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.78$-2.62$-2.34$-1.58$-1.18---
Avg Forecast$-2.60$-2.39$-2.41$-1.60$-1.20$-1.01$-1.20$-0.65
High Forecast$-1.77$-1.45$-2.39$-1.49$-0.74$-0.38$-0.44$-0.41
Low Forecast$-3.86$-3.59$-2.46$-1.74$-1.58$-1.53$-2.60$-0.89
Surprise %6.92%9.62%-2.90%-1.25%-1.67%---

Revenue Forecast

$0 $19M $38M $57M $76M $95M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.32M$19.23M$34.16M$22.60M$30.91M---
Avg Forecast$1.32M$22.92M$32.43M$29.46M$33.36M$38.50M$39.63M$70.81M
High Forecast$1.80M$31.77M$34.96M$41.19M$42.89M$39.29M$41.18M$91.03M
Low Forecast$990.88K$15.97M$29.23M$25.35M$24.03M$37.71M$38.09M$51.01M
Surprise %0.29%-16.11%5.32%-23.27%-7.34%---

Net Income Forecast

$-200M $-160M $-120M $-80M $-40M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-101.32M$-108.88M$-98.43M$-86.62M$-74.28M---
Avg Forecast$-109.30M$-100.21M$-101.78M$-67.92M$-48.58M$-40.21M$-95.00M$-27.13M
High Forecast$-74.26M$-60.73M$-100.11M$-62.66M$-30.89M$-16.09M$-18.66M$-17.27M
Low Forecast$-162.10M$-150.50M$-103.45M$-73.17M$-66.28M$-64.34M$-108.95M$-37.20M
Surprise %-7.30%8.66%-3.30%27.54%52.90%---

FHTX Forecast FAQ

Is Foghorn Therapeutics stock a buy?

Foghorn Therapeutics stock has a consensus rating of Buy, based on 12 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Foghorn Therapeutics is a favorable investment for most analysts.

What is Foghorn Therapeutics's price target?

Foghorn Therapeutics's price target, set by 12 Wall Street analysts, averages $4 over the next 12 months. The price target range spans from $2 at the low end to $5 at the high end, suggesting a potential 99.00% change from the previous closing price of $2.01.

How does Foghorn Therapeutics stock forecast compare to its benchmarks?

Foghorn Therapeutics's stock forecast shows a 99.00% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Foghorn Therapeutics over the past three months?

  • October 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 10.00% Strong Buy, 90.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Foghorn Therapeutics’s EPS forecast?

Foghorn Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.01, marking a -14.41% decrease from the reported $-1.18 in 2025. Estimates for the following years are $-1.2 in 2027, and $-0.65 in 2028.

What is Foghorn Therapeutics’s revenue forecast?

Foghorn Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $38.5M, reflecting a 24.56% increase from the reported $30.91M in 2025. The forecast for 2027 is $39.63M, and $70.8M for 2028.

What is Foghorn Therapeutics’s net income forecast?

Foghorn Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-40.214M, representing a -45.86% decrease from the reported $-74.283M in 2025. Projections indicate $-94.999M in 2027, and $-27.125M in 2028.